on Lobe Sciences Ltd. (CVE:LOBE)
Lobe Sciences Appoints Marco Mastrodonato to Board
Lobe Sciences Ltd., a clinical stage biopharmaceutical company, announced the appointment of Marco Mastrodonato to its Board of Directors. Mastrodonato brings extensive experience in the pharmaceutical and biotechnology sectors. He co-founded Sinclair Pharma plc. and led Metrodora Therapeutics Inc. He is also CEO of BMG Pharma, advancing hyaluronic acid-based technologies.
Dr. Fred Sancilio, Chairman and CEO of Lobe Sciences, expressed confidence in Mastrodonato's proven global business acumen. The company focuses on developing therapies for rare neurological and hematological conditions.
The Lobe Sciences pipeline includes Cynaptec Pharmaceuticals, working on Conjugated Psilocin for chronic cluster headaches, and Altemia, Inc., targeting sickle cell disease. The company emphasizes high-value, underserved markets.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lobe Sciences Ltd. news